Awiqli weekly insulin approval and availability

Awiqli is insulin icodec-abae, an FDA-approved once-weekly basal insulin for adults with type 2 diabetes. Its US label uses U-700 prefilled pens. Approval does not establish that it is stocked or offered at a particular clinic. Awiqli is labeled for adults with type 2 diabetes. A clinician assesses glucose control, current insulin, low-glucose history, monitoring ability, and whether a weekly schedule fits. The label is not a routine type 1 diabetes indication.

Yes. Novo Nordisk announced the nationwide US launch of Awiqli on August 11, 2026. As of October 9, 2026, its U-700 once-weekly basal-insulin pen is commercially available for qualifying adults with type 2 diabetes. Confirm whether your pharmacy can fill the prescription and how refills will be obtained. A switch requires the prescriber’s dose and monitoring plan; do not stop your current insulin while arranging it.

Yes. Awiqli is a once-weekly basal insulin for adults with type 2 diabetes. Use the prescribed weekly day and dose. Its initial transition dose and later doses need a clinician’s plan. Do not repeat a dose when uncertain whether it was taken.

U-700 means 700 insulin units in each milliliter. It is a concentration, not your prescribed dose. Use the Awiqli pen’s unit display and the exact prescribed instructions. Never draw insulin out of the pen with a syringe.

No. Initial switch doses, later weekly doses, timing, and monitoring differ by product and prior regimen. Multiplying the daily dose by seven yourself can cause dangerous low or high glucose. The prescriber must write the exact transition plan.

Call before traveling to confirm the exact service and appointment. An evaluation may require records, tests, or a later treatment decision. A general walk-in appointment does not guarantee medication, an injection, or specialist care that day. Bring daily basal and mealtime insulin details, devices, glucose reports, kidney results, and low-glucose history. Ask for product-specific storage and missed-dose instructions.

Arrange a review of your current condition and prescribed treatment without waiting for a new product. Bring daily basal and mealtime insulin details, devices, glucose reports, kidney results, and low-glucose history. Ask for product-specific storage and missed-dose instructions. Confirm the available service and clinician. Do not interrupt existing medicine yourself.

As of October 9, 2026, Medicare Part D may cover injectable insulin pens, but you must check whether your specific plan covers Awiqli and whether authorization is required. Medicare’s insulin cost limit applies to each covered insulin product: no more than $35 for a one-month supply, with no insulin deductible. It does not make every insulin brand a covered formulary choice. Part B’s insulin benefit generally concerns insulin used with a covered durable pump; Awiqli is a once-weekly pen medicine, not pump insulin. Ask the plan and pharmacy about the exact product and expected cost before switching, and confirm visit and supply charges separately.

The Awiqli label reports randomized trials in adults with type 2 diabetes comparing once-weekly Awiqli with daily basal insulin. Average A1c fell with Awiqli, including in people starting insulin and people changing from daily basal treatment. This supports its glucose-lowering use, but does not guarantee your response or mean weekly insulin eliminates low-glucose risk. The prescriber should review A1c, glucose patterns, current medicines and hypoglycemia history and arrange close monitoring during a switch. Awiqli is basal insulin; changing it does not automatically remove any separate mealtime-insulin requirement. Do not judge whether to switch from another person’s numbers or change your regimen yourself.